Healthcare
Establishment Labs Holdings Inc.(ESTA)
Live Price
Offline$84.81
+2.94% today
1Y Change
+132.56%
Window
Jun 25, 2025 โ Jun 24, 2026
- Market Cap
- $2.09B
- Revenue Growth
- +27.1%
- EPS Growth
- +42.7%
- Dividend Yield
- 0.0%
Coverage: 250 bars ยท Jun 25, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Establishment Labs Holdings Inc. (ESTA) is a Healthcare stock with a market cap of $2.09B and listed on NASDAQ. The stock last traded around $84.81 and up 132.6% across the available one-year price window (Jun 25, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of +27.1%, EPS growth of +42.7%, a dividend yield of 0.0%. What stands out right now is revenue +27.1%, EPS +42.7%, free cash flow +23.1% with operating margin -18.5% and ROIC -11.9%. Valuation already assumes a fairly strong business story at price/sales 9.9. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines ESTA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+27.1% vs +7.6% peer median
Operating Margin
Below sector median
-18.5% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 6, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +27.1% and EPS at +42.7%, with operating margin around -18.5%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -4.5% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | โ | -3.4% | -7.3% | +2.6% |
2026 Feb 24, 2026 | +58.1% | -1.7% | -10.7% | -27.0% |
2025 Nov 5, 2025 | +29.6% | +7.3% | +4.4% | +16.9% |
Benchmark Edge
ESTA vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ESTA
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ESTA Max Drawdown
-31.35%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ESTA and SPY.
Company Overview
Establishment Labs Holdings Inc.
NASDAQ Capital Market
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution. The company sells its products through exclusive distributors and direct sales force in Europe, Latin America, the Asia-Pacific, and internationally. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.
- Leadership
- Fillipo Peter Caldini
- IPO Date
- Jul 19, 2018
- Employees
- 1.0k
- Street Address
- Building B15 and 25
- Mailing
- Alajuela
- Region
- Alajuela, CR
- Reporting Currency
- USD
- Investor Line
- 506 2434 2400
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 9.9
- Price/Book
- 89.3
Growth
- Revenue
- +27.1%
- EPS
- +42.7%
- Free Cash Flow
- +23.1%
Profitability
- Gross Margin
- 69.3%
- Operating Margin
- -18.5%
- Net Margin
- -24.2%
- ROE
- -201.8%
- ROIC
- -11.9%
Balance Sheet
- Debt/Equity
- 11.23
- Current Ratio
- 3.04
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.